AstraZeneca’s Ian Brimicombe discusses its global transfer pricing strategy

Ian Brimicombe, VP of corporate finance for multinational pharmaceutical company AstraZeneca, discusses his company’s global transfer pricing strategy, including how it is focusing on the BEPS debate and the tax motivations of US companies looking to relocate to the UK.

Locked content

The article you are trying to view is only available to subscribers and current trialists